Inhibitex Stock up 150% in Pre-Market (BMY, INHX)

Photo of Paul Ausick
By Paul Ausick Published

Bristol-Myers Squibb (NYSE: BMY) will pay $2.5 billion in cash (a 163% premium to Friday’s closing price) for hepatitis C drug developer Inhitibex Inc. (NASDAQ: INHX).

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

HPE Vol: 153,197,465
ENPH Vol: 8,360,053
GLW Vol: 18,152,646
APTV Vol: 6,761,325

Top Losing Stocks

TTD Vol: 21,905,513
INTU Vol: 7,383,018
CTRA Vol: 73,319,495
CBOE Vol: 5,000,011
HP
HPQ Vol: 29,259,826